B. Riley Lifts Earnings Estimates for Kymera Therapeutics

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities researchers at B. Riley raised their Q2 2025 earnings per share estimates for Kymera Therapeutics in a report issued on Monday, May 12th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($1.01) per share for the quarter, up from their prior estimate of ($1.02). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.85) EPS, FY2026 earnings at ($3.88) EPS, FY2027 earnings at ($3.88) EPS and FY2028 earnings at ($3.80) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company’s revenue for the quarter was up 114.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.69) earnings per share.

A number of other research analysts have also issued reports on KYMR. Guggenheim reissued a “buy” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Monday. Bank of America dropped their price objective on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a report on Monday. Stephens reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. UBS Group dropped their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, HC Wainwright upped their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $55.27.

Kymera Therapeutics Trading Down 3.2%

NASDAQ:KYMR opened at $31.14 on Wednesday. The firm has a market cap of $2.03 billion, a P/E ratio of -13.31 and a beta of 2.18. The stock’s 50 day simple moving average is $29.55 and its 200-day simple moving average is $37.36. Kymera Therapeutics has a 12-month low of $19.45 and a 12-month high of $53.27.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock worth $276,395,000 after buying an additional 224,859 shares during the period. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after buying an additional 688,967 shares during the period. Vanguard Group Inc. lifted its position in Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares during the period. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares during the period. Finally, Driehaus Capital Management LLC lifted its position in Kymera Therapeutics by 4.6% during the fourth quarter. Driehaus Capital Management LLC now owns 1,390,372 shares of the company’s stock worth $55,935,000 after buying an additional 61,669 shares during the period.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 over the last three months. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.